Print Page   |   Contact Us   |   Sign In   |   Join iBIO
Industry News


TOP industry news from Business Wire

Palladio Biosciences Announces Dosing of First Patients with Lixivaptan in ELiSA, a Phase 2 Clinical Study in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)Open in a New Window

NEWTOWN, Pa.--(BUSINESS WIRE)--Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients are now being dosed with lixivaptan in ELiSA Phase 2 clinical study.

 

ArTara Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on Choline Chloride for Injection for Intestinal Failure Associated Liver Disease (IFALD)Open in a New Window

NEW YORK--(BUSINESS WIRE)--ArTara Therapeutics, a clinical-stage company developing treatments for rare diseases with significant unmet needs, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss study of Intravenous (IV) Choline Chloride substrate replacement for patients with Intestinal Failure Associated Liver Disease (IFALD). IFALD is a devastating disease that impacts a large number of patients who rely on

 

Propanc Biopharma Selects LaVoieHealthScience as Integrated Communications PartnerOpen in a New Window

MELBOURNE, Australia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/PPCH?src=hash" target="_blank"gt;#PPCHlt;/agt;--Propanc Biopharma Selects LaVoieHealthScience as Integrated Communications Partner

 

Emulate, Inc. Awarded Grant to Use Intestine-Chip to Study Human GI Infections Aboard the International Space StationOpen in a New Window

BOSTON--(BUSINESS WIRE)--Emulate, Inc. was awarded a grant to use its Intestine-Chip to study human GI infections aboard the International Space Station.

 

Wearable Sweat Sensor Pioneer Issued Key Device PatentOpen in a New Window

CINCINNATI--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IP?src=hash" target="_blank"gt;#IPlt;/agt;--Wearable sweat sensor pioneer Eccrine Systems announces issuance of key patent on invention providing chronological assurance of sweat analyte data.

 

Celgene Corporation to Present at the 37th Annual J.P. Morgan Healthcare ConferenceOpen in a New Window

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) will present a business update and provide 2019 financial guidance at the 37th Annual J.P. Morgan Healthcare Conference on January 7, 2019 at 7:30 a.m. PT/ 10:30 a.m. ET. The presentation and breakout session can be accessed live by webcast and will be made available in the Investor Relations section of the Company’s website at www.celgene.com. About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrate

 

Multiverse Investment Fund Begins Operations in West Los AngelesOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Multiverse Investment Fund I, LP (Multiverse) (http://www.multiverseinvestmentfund.com) a venture fund geared to investing in gatekeeper bio and high tech companies with potential for significant positive social impact and financial returns, has been launched in West Los Angeles, it was announced by Jack Kavanaugh, one of the managing members of Multiverse’s general partner. Kavanaugh is a former founder, Chairman and CEO of ZetaRx which became the heart and core of J

 

NorthStar Medical Technologies, LLC Announces Appointment of Paul Estrem, CPA, as Senior Vice President and Chief Financial OfficerOpen in a New Window

BELOIT, Wis.--(BUSINESS WIRE)--Paul Estrem, CPA, is appointed Senior Vice President and Chief Financial Officer of NorthStar Medical Technologies, LLC.

 

Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150Open in a New Window

BOSTON--(BUSINESS WIRE)--Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150

 

Cerus Completes CE Mark Submission for INTERCEPT Red Blood CellsOpen in a New Window

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell (RBC) system. “The INTERCEPT RBC CE Mark submission is a major milestone in the Company’s history and represents the culmination of years of effort to complete the full INTERCEPT portfolio of products to help ensure that patients have access to safe blood transfusions,” said William ‘Obi’ Greenman, the Company’s president and chi

 

Zoetis to Participate in the 37th Annual J.P. Morgan Healthcare ConferenceOpen in a New Window

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ZTS&src=ctag" target="_blank"gt;$ZTSlt;/agt; lt;a href="https://twitter.com/hashtag/investor?src=hash" target="_blank"gt;#investorlt;/agt;--Zoetis to participate in the 37th Annual J.P. Morgan Healthcare Conference on Jan. 9.

 

Paula LeClair Joins Glytec as Executive Director and General Manager, OutpatientOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/A1C?src=hash" target="_blank"gt;#A1Clt;/agt;--Glytec welcomes Paula LeClair as Executive Director and General Manager, Outpatient.

 

Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product LineOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. Announces the Sale of its Surgical Product Line

 

Context Therapeutics Announces Key Additions to its Board of DirectorsOpen in a New Window

PHILADELPHIA--(BUSINESS WIRE)--Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to the treatment of hormone-responsive cancers, today announced two key additions to its board of directors. Philip Kantoff, MD, Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center has been appointed to Context Therapeutics’ board of directors, bringing more than 30 years of leadership in clinical oncology practice, research and drug development. Elizabeth McKee

 

Global Hemostasis Diagnostics Market Players Report 2018: Market Shares by Country, Strategic Assessments of Major Suppliers and Emerging Market Entrants - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "2018 Global Hemostasis Diagnostics Market Players - Market Shares by Country, Strategic Assessments of Major Suppliers and Emerging Market Entrants" report has been added to ResearchAndMarkets.com's offering. This new report provides strategic assessments of major suppliers of hemostasis diagnostic products, as well as emerging market entrants. The report presents analyses of major current and emerging suppliers of hemostasis instruments and reagents, including: Sa

 

RiverVest Venture Partners Closes on Oversubscribed $184.4 Million Life Sciences FundOpen in a New Window

ST. LOUIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/VC?src=hash" target="_blank"gt;#VClt;/agt;--RiverVest Venture Partners closes on oversubscribed $184.4 million life sciences fund dedicated to developing biopharma and medical device products.

 

武田獲得CHMP肯定意見,接納ADCETRIS® (brentuximab vedotin)聯合AVD用於治療既往未曾治療的CD30+ IV期何杰金氏淋巴瘤成人患者Open in a New Window

麻塞諸塞州劍橋和日本大阪--(BUSINESS WIRE)--(美國商業資訊) -- 武田藥品工業株式會社(TSE: 4502)今天宣布,歐洲藥品管理局(EMA)人用藥品委員會(CHMP)採納了一項肯定意見,延長ADCETRIS (brentuximab vedotin)的上市許可,並推薦核准該藥聯合AVD用於既往未曾治療的CD30+ IV期何杰金氏淋巴瘤成人患者。ADCETRIS是一種抗體藥物複合物(ADC),可靶向作用於何杰金氏淋巴瘤代表性標記物CD30。ADCETRIS目前尚未在歐洲獲准用於既往未曾治療的何杰金氏淋巴瘤。 加泰羅尼亞腫瘤研究所- Duran i Reynals醫院血液科和造血幹細胞移植計畫主任Anna Sureda, M.D., Ph.D.表示:「大量診斷為IV期的既往未曾治療的何杰金氏淋巴瘤患者在現行治療期間病情進展,說明該群體確實存在未獲滿足的需求。ECHELON-1臨床試驗顯示,在IV期患者中,ADCETRIS聯合AVD組的進展、死亡或需要後續抗癌藥的風險比標準治療ABVD組低29%。ADCETRIS如果在歐洲獲准用於該適應症,可向既往未曾治療的IV期何杰

 

武田获得CHMP肯定意见,接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者Open in a New Window

马萨诸塞州剑桥和日本大阪--(BUSINESS WIRE)--(美国商业资讯) -- 武田药品工业株式会社(TSE: 4502)今天宣布,欧洲药品管理局(EMA)人用药品委员会(CHMP)采纳了一项肯定意见,延长ADCETRIS (brentuximab vedotin)的上市许可,并推荐核准该药联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者。ADCETRIS是一种抗体-药物螯合物(ADC),可靶向作用于霍奇金淋巴瘤标志性标记物CD30。ADCETRIS目前尚未在欧洲获准用于既往未曾治疗的霍奇金淋巴瘤。 加泰罗尼亚肿瘤研究所- Duran i Reynals医院血液科和造血干细胞移植项目主任Anna Sureda, M.D., Ph.D.表示:“大量诊断为IV期的既往未曾治疗的霍奇金淋巴瘤患者在现行治疗期间病情进展,说明该群体确实存在未获满足的需求。ECHELON-1临床试验显示,在IV期患者中,ADCETRIS联合AVD组的进展、死亡或需要后续抗癌药的风险比标准治疗ABVD组低29%。ADCETRIS如果在欧洲获准用于该适应证,可向既往未曾治疗的IV期霍奇金淋巴

 

Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical OperationsOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics today announced the addition of two senior leaders and relocated to expanded R&D facilities in Bedford, Mass.

 

Semma Therapeutics Expands Executive Leadership TeamOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Semma Therapeutics, Inc., a biotechnology company pioneering the curative use of stem cells in regenerative medicine, today announced the appointments of David Lebwohl, M.D., as Chief Medical Officer and David DiGiusto, Ph.D., as Chief Technology Officer and Ann Darda as Head of Human Resources. “We are pleased to welcome Drs. Lebwohl, DiGiusto, and Ms. Darda to Semma,” said Bastiano Sanna, Ph.D., Chief Executive Officer and President, Semma Therapeutics. “Cel

 

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical DevelopmentOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

 

Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 InhibitorOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Earns $8 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development for First-in-Class PRMT1 Inhibitor

 

富士制药向Alvotech投资5000万美元Open in a New Window

东京和冰岛雷克雅未克--(BUSINESS WIRE)---- (美国商业资讯) -- 生物制药公司Alvotech今天宣布,总部位于日本的富士制药出资约5000万美元收购其4.2%的股权。 Alvotech与富士制药最近宣布一份在日本开发和商业化生物类似物的排他性协议。富士制药对Alvotech的投资进一步加强了两家公司之间的伙伴关系,体现了两家公司的长期承诺。 此次交易后,Alvotech的关键股东是Aztiq Pharma AB(由Robert Wessman领导的控股股东)、仿制药公司Alvogen和富士制药。 Alvotech的当前产品线包括旨在治疗癌症、自身免疫病、炎性疾病和其他疾病的6个生物类似物单克隆抗体,预计首个产品将在2020年前上市。Alvotech自2013年成立以来,已投资于一个高价值产品线,并在冰岛雷克雅未克新设了一家尖端生物制药厂。开发中心设在德国和瑞士,聘用超过250位科学家。 Alvotech创始人Robert Wessman表示:“Alvotech已将自身建设成为一家完全一体化的生物制药公司,跨越生物类似物的细胞株开发到制造、临床开发和注册。我欣然

 

富士製藥對Alvotech投資5000萬美元Open in a New Window

東京和冰島雷克雅維克--(BUSINESS WIRE)---- (美國商業資訊) -- 生物製藥公司Alvotech今天宣佈,總部位於日本的富士製藥出資約5000萬美元收購其4.2%的股權。 Alvotech與富士製藥最近宣佈達成在日本開發生物相似性藥品並進行商業化的排他性協議。富士製藥對Alvotech的投資進一步加強了兩家公司之間的合作夥伴關係並反映兩家公司的長期承諾。 此次交易後,Alvotech的關鍵股東是Aztiq Pharma AB(由Robert Wessman領導的控股股東)、學名藥製藥公司Alvogen和富士製藥。 Alvotech目前的產品線包括旨在治療癌症、自體免疫疾病、發炎性疾病和其他疾病的6個生物相似性單株抗體,預計首批產品將在2020年前上市。自2013年成立以來,Alvotech已投資於高價值產品線,並在冰島雷克雅維克新設尖端的生物製藥廠。開發中心設在德國和瑞士,聘用超過250位科學家。 Alvotech創辦人Robert Wessman表示:「Alvotech已將自身建設為一家完全整合的生物製藥公司,跨越生物相似性藥品的細胞株開發到製造、臨床開發和註冊

 

2018 Cell Surface Markers: US, Europe, Japan - Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "2018 Cell Surface Markers: US, Europe, Japan - Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering. The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is furthe

 

PredictImmune Makes Further Strides Towards January Launch of PredictSURE IBD™, by Gaining ISO 13485 Medical Devices CertificationOpen in a New Window

CAMBRIDGE, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IBD?src=hash" target="_blank"gt;#IBDlt;/agt;--PredictImmune makes further strides towards January launch of PredictSURE IBD™, by gaining ISO 13485 medical devices certification

 

Acticor Biotech Appoints Dr Andrea Comenducci as Medical DirectorOpen in a New Window

PARIS--(BUSINESS WIRE)--Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombo-embolic diseases, including stroke and pulmonary embolism, today announced the appointment of Dr Andrea Comenducci MD as Medical Director in charge of clinical R&D and medical affairs. Dr Comenducci specialises in the cardiovascular field, and his priority will be to lead, with the support of a strengthened clinical team, the current Phase II clinical trial of ACT017, Actic

 

武田薬品、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者を治療するためのアドセトリス(ブレンツキシマブ・ベドチン)とAVDの併用に関するCHMPの肯定的見解を受領Open in a New Window

米マサチューセッツ州ケンブリッジ & 大阪--(BUSINESS WIRE)--(ビジネスワイヤ) -- 武田薬品工業株式会社(TSE: 4502)は本日、欧州医薬品庁(EMA)の医薬品評価委員会(CHMP)が、アドセトリス(ブレンツキシマブ・ベドチン)の市販承認の範囲拡大に対する肯定的見解を採用し、未治療のCD30陽性ステージ4ホジキンリンパ腫成人患者におけるAVDとの併用療法の適応拡大について、承認を勧告したと発表しました。アドセトリスは、ホジキンリンパ腫を特徴付けるマーカーCD30を標的とする抗体薬物複合体(ADC)です。 アドセトリスは現在、未治療のホジキンリンパ腫に対する治療薬として欧州で承認されていません。 Duran i Reynals病院カタルーニャ腫瘍センターで血液科および造血幹細胞移植プログラムの責任者を務めるAnna Sureda医師(M.D.、Ph.D.)は、次のように述べています。「ステージ4と診断された未治療ホジキンリンパ腫患者の多くにとって、現在の治療では病状が進行し、この患者集団でまさに未充足ニーズが浮き彫りになっています。ECHELON-1臨床試験で

 

OncoImmunity erhält 2,2 Mio. Euro zur Einführung seiner Maschinenlernplattform für die Entwicklung von personalisierten KrebsimmuntherapienOpen in a New Window

OSLO, Norwegen--(BUSINESS WIRE)--Das Bioinformatikunternehmen OncoImmunity hat einen Zuschuss aus dem angesehenen KMU-Finanzierungsinstrument der EU erhalten. Das Hauptprodukt des Unternehmens, der ImmuneProfiler™, ist eine einzigartige Plattform für maschinelles Lernen, die Beiträge zur Lösung des Problems der Neoantigen-Prognose geleistet hat. OncoImmunity ist seinen Partnern behilflich, das einer „Nadel im Heuhaufen“ gleichende Problem der Identifizierung des richtigen Antigen-Cocktails für

 

AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax CreditOpen in a New Window

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax Credit Incentive program provides a cash rebate to support companies in Australia conducting research and development projects. Projects undertaken by AVITA Medi

 

Riassunto: OncoImmunity riceve 2,2 milioni di euro per realizzare la piattaforma di apprendimento automatico volta a consentire lo sviluppo di immunoterapie oncologiche personalizzateOpen in a New Window

OSLO, Norvegia--(BUSINESS WIRE)--La società di bioinformatica OncoImmunity ha ricevuto il prestigioso finanziamento dell'UE SME Instrument. Il prodotto di punta della società, ImmuneProfiler™, è un'esclusiva soluzione di apprendimento automatico che ha fatto passi avanti nel risolvere la sfida della predizione dei neoantigeni. OncoImmunity consente ai collaboratori di risolvere la sfida dell'“ago nel pagliaio” di identificare la corretta miscela di neoantigeni per ciascun paziente e progettare

 

OncoImmunity reçoit 2,2 millions d'euros pour déployer sa plateforme d'apprentissage automatique qui permettra le développement d'immunothérapies personnalisées contre le cancerOpen in a New Window

OSLO, Norvège--(BUSINESS WIRE)--La société de bioinformatique OncoImmunity a reçu le prestigieux financement européen à destination des PME. Le produit phare de la société, l' ImmuneProfiler™, est une solution d'apprentissage automatique unique qui a réussi à résoudre le problème de la prédiction de néo-antigènes. OncoImmunity permet à leurs partenaires de résoudre le problème de « l'aiguille dans la botte de foin » pour identifier le bon cocktail de néo-antigènes pour chaque patient, et de con

 

Aptorum Group Limited Announces Closing of Initial Public OfferingOpen in a New Window

HONG KONG--(BUSINESS WIRE)--Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced the closing of its initial public offering (“IPO” or the “Offering”) of 761,419 Class A Ordinary Shares, at a public offering price of $15.80 per share. The aggregate gross proceeds to Aptorum from the

 

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)Open in a New Window

PASADENA, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24arwr&src=ctag" target="_blank"gt;$arwrlt;/agt;--Arrowhead reports inducement grants

 

Pulse Biosciences Grants Equity Incentive Awards to New EmployeesOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences Grants Equity Incentive Awards to New Employees

 

Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in PlantsOpen in a New Window

MINNEAPOLIS & ST. PAUL, Minn.--(BUSINESS WIRE)--Calyxt Receives EU Patent on Use of CRISPR/Cas9 for Genome Editing in Plants

 

Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and ResistanceOpen in a New Window

NEW YORK & BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24BMY&src=ctag" target="_blank"gt;$BMYlt;/agt; lt;a href="https://twitter.com/hashtag/BMS?src=hash" target="_blank"gt;#BMSlt;/agt;--Bristol-Myers Squibb and Boston Medical Center Announce Research Collaboration to Investigate Markers of Immuno-Oncology Response and Resistance

 

Motus GI Announces Launch of Proposed Follow-on Public OfferingOpen in a New Window

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed follow-on public offering of 5,000,000 shares of its common stock. In addition, the Company intends to grant the underwrite

 

Ligand Acquires Milestone and Royalty Rights to PTX-022 from Palvella TherapeuticsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics. PTX-022 is a novel, topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita (PC), a rare skin disorder for which no FDA-approved treatment exists. Ligand will pay $10 million to Palvella Therapeutics and in return will receive a tiered royalty on net sales in the mid-to-upper sin

 

OncoImmunity Receives €2.2 Million to Roll out Its Machine-Learning Platform to Enable the Development of Personalized Cancer ImmunotherapiesOpen in a New Window

OSLO, Norway--(BUSINESS WIRE)--The bioinformatics company OncoImmunity has been awarded the prestigious EU SME Instrument funding. The company’s flagship product, the ImmuneProfiler™, is a unique machine learning solution that has made inroads into solving the neoantigen prediction challenge. OncoImmunity enables their partners to solve the “needle in the haystack” challenge of identifying the right cocktail of neoantigens for each individual patient, and design a vaccine or cell therapy unique

 

Mobidiag gibt Joint Venture mit Autobio Diagnostics und Kapitalbeteiligung in Höhe von 10 Mio. Euro bekanntOpen in a New Window

ESPOO, Finnland--(BUSINESS WIRE)--Mobidiag Ltd., ein Anbieter vermarktungsreifer Molekulardiagnostiklösungen, der sich mit der Ausbreitung antimikrobieller Resistenz auseinandersetzt, gab den Abschluss eines Vertrags über ein Joint Venture (JV) mit Autobio Diagnostics („Autobio“), einem führenden Anbieter von klinischer Diagnostik in China, bekannt. Zweck des Joint Venture ist die Vermarktung der Novodiag®-Plattform in China. Außerdem hat Mobidiag nach eigenen Angaben eine separate Beteiligungs

 

Cell Separation & Characterization in Solid Tumors: Global Markets Through 2023 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Cell Separation and Characterization in Solid Tumors: Global Markets Through 2023" report has been added to ResearchAndMarkets.com's offering. This report consists of the overall analysis of the market landscape. It provides in-depth analysis on market size, growth opportunity in market and product types. The report will serve as a source for 360-degree analysis of the market, thoroughly integrating different models. The report will help the companies and organizat

 

Biomarker Deals: Terms, Value and Trends (2008-2018) - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Biomarker Deals: Terms, Value and Trends, 2008-2018" report has been added to ResearchAndMarkets.com's offering. This report represents a current and important business tool to evaluate terms and conditions of licensing, acquisitions and partnerships deals in the biomarker sector. The geographic scope of this study covers the U.S. and companies worldwide. The report identifies the main elements in licensing, acquisitions and partnership deals in the biomarker indus

 

Siren Announces Publication of Foundational Data for Novel Approach to Skin Temperature Monitoring in Journal of Medical Internet Research (JMIR)Open in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Promising results from the first at-home, continuous wireless temperature-monitoring system to detect the onset of diabetic foot ulcers

 

Tivic Health™ to Demonstrate ClearUP™ Sinus Pain Relief Device At CES 2019Open in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/ClearUP?src=hash" target="_blank"gt;#ClearUPlt;/agt;--Tivic Health, a bioelectronic device company, will demonstrate ClearUP™ Sinus Pain Relief – the first bioelectronic treatment for sinus pain at CES.

 

Medical Researchers Find a Biomarker for Non-Celiac Gluten SensitivityOpen in a New Window

DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Although only an estimated 1% of the US population has celiac disease, millions more, 11% of US households, eat gluten free. Celiac is an autoimmune disease whereby the immune cells attack the lining of the small intestine, resulting in malabsorption and greater risk of diabetes and other autoimmune disorders. Strict avoidance of gluten is mandatory for people with celiac disease. But, millions of people believe they suffer from gluten sensitivity, also k

 

Samenvatting: Mobidiag Kondigt Joint Venture aan met Autobio Diagnostics met een €10m kapitaalinjectieOpen in a New Window

ESPOO, Finland--(BUSINESS WIRE)--Mobidiag Ltd., een moleculair diagnostisch bedrijf dat zich bezighoudt met de verspreiding van antimicrobiële resistentie, kondigt vandaag aan dat het een joint venture (‘JV’) is aangegaan met Autobio Diagnostics (‘Autobio’), een van de toonaangevende klinische diagnostische bedrijven in China, om het Novodiag® platform in China te commercialiseren. Daarnaast kondigt Mobidiag aan dat het een aparte investering van 10 miljoen euro in aandelen van Autobio heeft ve

 

Global Healthcare Exoskeletons Market 2018-2023 by Application, Mobility Type, Product Function, Power Technology, and Region - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Global Healthcare Exoskeletons Market by Application, Mobility Type, Product Function, Power Technology, and Region 2018-2023: Growth Opportunity and Business Strategy" report has been added to ResearchAndMarkets.com's offering. During 2018-2023, global demand for healthcare exoskeletons is poised to a cumulative market value of over $2.405 billion including direct sales, renting, leasing, insurance reimbursement and other revenue sources. In terms of unit shipment

 

Samenvatting: Tilray® kondigt Internationale Adviesraad aanOpen in a New Window

NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ:TLRY), een wereldwijde pionier in cannabisproductie en distributie, kondigt vandaag de formatie aan van zijn Internationale Adviesraad, een gerespecteerde groep van zakelijke en politieke leiders die richting zullen geven aan het bestuur van Tilray en de Raad van Directeurs, nu het bedrijf een agressieve groeistrategie uitvoert op wereldwijd niveau. “We zijn vereerd om deze indrukwekkende groep gerespecteerde leiders te mogen verw

 

Global Infectious Disease Therapeutics Market 2019-2023 | Development of Novel Drugs to Boost Demand | TechnavioOpen in a New Window

LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/HealthCare?src=hash" target="_blank"gt;#HealthCarelt;/agt;--The global infectious disease therapeutics market is set to post a CAGR of over 4% during the period 2019-2023, according to Technavio.

 

Ayala Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study of Lead Product Candidate AL101 for Adenoid Cystic Carcinoma with Notch Activated MutationsOpen in a New Window

REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, today announced that the first patient has been enrolled in its Phase 2 ACCURACY study, to evaluate lead investigational candidate AL101 in patients with adenoid cystic carcinoma (ACC) bearing Notch activated mutations. AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activatio

 

Instem Reports Increased Market Demand for KnowledgeScan Target Safety Assessment ServiceOpen in a New Window

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Instem Reports Increased Demand for KnowledgeScan Target Safety Assessment Service. Delivering Comprehensive Insight into Biological Target Profiling

 

Association Management Software Powered by YourMembership  ::  Legal